timothy sykes logo
CMPS Stock Jumps As White House Backs Psychedelic Therapies Thumbnail
ADD US ONG Google News

CMPS Stock Jumps As White House Backs Psychedelic Therapies

ELLIS HOBBS•UPDATED APR. 20, 2026, 9:19 AM ET
Reviewed by Matt Monaco Fact-checked by Bryce Tuohey

COMPASS Pathways Plc stocks have been trading up by 28.35 percent after promising mental health treatment trial results buoyed investors

Candlestick Chart

Live Update At 09:18:38 EDT: On Monday, April 20, 2026 COMPASS Pathways Plc stock [NASDAQ: CMPS] is trending up by 28.35%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CMPS has shifted from quiet biotech to active trading vehicle over the last few weeks. On the daily chart, CMPS has climbed from around $5.24 on 2026/03/30 to $6.66 by 2026/04/17, a roughly 27% move in less than three weeks. That kind of steady grind higher tells traders that dip‑buyers are in control for now.

The intraday tape backs that up. Pre‑market data show CMPS repeatedly holding the low‑$8s and pushing toward the mid‑$8s and even low‑$9s on spikes, a classic sign of momentum traders leaning long and scalping volatility. Pullbacks keep getting bought instead of flushing.

Under the hood, Compass Pathways is still a loss‑making biotech. In the latest 2025 quarterly report, CMPS posted about -$137.7M in net income and free cash flow around -$35.1M, with a return on invested capital near -67.55%. Those are brutal numbers on paper, but normal for a company funding big Phase 3 programs. The key for traders is runway: CMPS ended the quarter with about $186M in cash and says its financing now carries operations into 2028, giving it time to chase FDA approval and potential launch.

Why Traders Are Watching CMPS Now

CMPS is turning into a textbook catalyst story, driven by both Washington and Wall Street. The biggest macro jolt came from the new White House Executive Order aimed at accelerating research, regulatory review, and access for psychedelic‑based treatments for serious mental illness. Compass Pathways publicly applauded that move, saying it lines up almost perfectly with its COMP360 psilocybin program and ongoing rolling NDA with the FDA.

For active traders, that matters. Policy support can shift the whole risk‑reward profile. When the U.S. government signals it wants faster paths for psychedelic therapies, a late‑stage name like CMPS suddenly jumps toward the front of the line. That helps explain why psychedelic‑focused biotech names, including CMPS, have been bid up on expectations of a friendlier regulatory and funding environment.

On the company‑specific side, Compass Pathways has already delivered two positive Phase 3 trials of COMP360 in treatment‑resistant depression and is targeting completion of its rolling NDA in Q4 2026. Management says it wants CMPS ready for commercial launch by the end of 2026. That’s a defined timeline, and traders love clocks they can trade around.

Wall Street is paying attention. Stifel lifted its CMPS price target from $11 to $14 with a Buy rating after Q4 earnings, pointing to strong Phase 3 and durability data plus NDA progress. Morgan Stanley nudged its target down from $18 to $16 but kept an Overweight rating, and Canaccord trimmed from $20 to $18 while maintaining Buy. The message: CMPS is risky, but the Street still views the clinical story as intact and compelling.

At the same time, Compass Pathways is broadening the COMP360 opportunity. CMPS has kicked off a late‑stage PTSD program and launched a U.S. grant initiative to fund post‑approval training for healthcare providers who will deliver COMP360 therapy. That tells seasoned traders the company is already thinking past approval to real‑world rollout, which can be a key edge versus smaller, less organized biotech names.

More Breaking News

Conclusion

For active traders, CMPS sits at the intersection of hype, hard data, and heavy losses. The latest quarter showed a wider Q4 loss of about -$1.00 per share versus -$0.63 a year earlier, as Compass Pathways poured cash into late‑stage trials and commercial prep. But those losses are now backed by a much stronger balance sheet: roughly $150M in new financing plus $200M in warrant exercises, pushing the cash runway into 2028 and lowering near‑term financing fears.

What keeps CMPS on so many watchlists is the catalyst stack. Two positive Phase 3 trials in treatment‑resistant depression, a rolling NDA targeted for completion in 2026, a planned end‑2026 commercial launch, and a new White House policy that explicitly favors psychedelic therapies. Add in expansion into PTSD and provider‑training grants, and you have a clear story of Compass Pathways trying to lock down both approval and adoption.

Traders still have to respect the risk. CMPS is a clinical‑stage biotech with no current product revenue, a negative ROIC, and ongoing dilution pressure. This is not a widows‑and‑orphans stock; it is a catalyst‑driven trading vehicle. As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. As Tim Sykes likes to hammer home, “The market doesn’t care about your opinion, only about price and volume. Cut losses quickly and only ride momentum you fully understand.” For CMPS, that means studying the chart, tracking every regulatory headline, and treating each move as a trade, not a promise.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CMPS

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”